Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Notes underwriting agrmnt
|
|
EMMAUS LIFE SCIENCES, INC.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/31/2019 |
SC 13D/A
| Niihara Yutaka reports a 0% stake in EMI Holding, Inc. |
| 07/22/2019 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 07/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/08/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/08/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/03/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/03/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/24/2019 |
8-K
| Quarterly results |
| 06/24/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/14/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 05/14/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 03/21/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 03/11/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/11/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/04/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/29/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/24/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/14/2019 |
SC 13D/A
| Niihara Yutaka reports a 31.6% stake in Emmaus Life Sciences, Inc. |
| 01/10/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/07/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/07/2019 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Agreement and Plan of Merger and Reorganization, by and among MYnd Analytics, Inc., Athena Merger Subsidiary, Inc. and Emmaus Life Sciences, Inc",
"Form of Emmaus Voting Agreement, including form of irrevocable proxy",
"Form of MYnd Voting Agreement, including form of irrevocable proxy",
"Form of Emmaus Lock-Up Agreement",
"Form of MYnd Lock-Up Agreement",
"CFO, Emmaus Life Sciences, Inc." |
|
| 01/07/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/20/2018 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 12/14/2018 |
SC 13D/A
| Niihara Yutaka reports a 31.6% stake in Emmaus Life Sciences, Inc. |
| 11/30/2018 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/14/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/01/2018 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 10/15/2018 |
8-K
| Quarterly results |
| 10/05/2018 |
8-K/A
| Quarterly results |
| 09/28/2018 |
8-K
| Quarterly results |
| 09/17/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits|
Docs:
|
"Form of 10% Senior Secured Debenture",
"Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement among Emmaus Life Sciences, Inc. and the Purchasers thereunder",
"Form of Security Agreement among Emmaus Life Sciences, Inc., Emmaus Medical, Inc., Newfield Nutrition Corporation and the holders of 10% Senior Secured Debentures",
"Form of Subsidiary Guarantee among Emmaus Medical, Inc., Newfield Nutrition Corporation and the holders of 10% Senior Secured Debentures",
"Fee Agreement made as of August 24, 2018 between Emmaus Life Sciences, Inc. and T.R. Winston & Company, LLC" |
|
| 08/23/2018 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/14/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 07/19/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|